Register
Login:
Share:
Email Facebook Twitter

#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects Watch Here

#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects
EXCLUSIVE: Petro Matad announce fully funded 4 well Mongolia campaign




Share Price Information for Akers Bio (AKR)


Share Price: 87.50Bid: 80.00Ask: 95.00Change: 0.00 (0.00%)No Movement on Akers Bio
Spread: 15.00Spread as %: 18.75%Open: 87.50High: 87.50Low: 87.50Yesterday’s Close: 87.50

Akers Biosciences, Inc. Com Shs Npv

Akers Bio is listed in the FTSE AIM All-Share
Akers Bio is part of the Health Care and Related Services sector






Share Price SpacerPrice
87.50
Share Price SpacerBid
80.00
Share Price SpacerAsk
95.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
87.50
Share Price SpacerHigh
87.50
Share Price SpacerLow
87.50
Share Price SpacerClose
87.50
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 12.47m £10.91m 300

52 Week High 147.50 52 Week High Date 20-NOV-2018
52 Week Low 10.00 52 Week Low Date 10-AUG-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -0.241 -363.10 0.00 0.00


London South East Users info for Akers Bio




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

11-Jan-19
08:17:08
80.00
133
Sell* 
80.00
95.00
106.40
Trade Type:
Ordinary

10-Jan-19
15:49:25
80.00
1
Sell* 
80.00
95.00
0.80
Trade Type:
Ordinary

10-Jan-19
12:30:12
80.00
482
Sell* 
80.00
95.00
385.60
Trade Type:
Ordinary




View more Akers Bio trades >>

Directors Deals for Akers Bio (AKR)
Trade DateActionNotifierPriceCurrencyAmountHolding
27-Dec-18Transfer From
Trade Notifier Information for Akers Biosciences, Inc.
Howard R. Yeaton held the position of CEO at Akers Biosciences, Inc. at the time of this trade.
 Howard R. Yeaton
03,7507500
27-Dec-18Transfer From
Trade Notifier Information for Akers Biosciences, Inc.
Howard R. Yeaton held the position of CEO at Akers Biosciences, Inc. at the time of this trade.
 Howard R. Yeaton
03,7507500
24-May-16Buy
Trade Notifier Information for Akers Biosciences, Inc.
John J. Gormally held the position of CEO at Akers Biosciences, Inc. at the time of this trade.
 John J. Gormally
2.19USD692500
View more Akers Bio directors dealings >>


fuelforlove
Posts: 36
Opinion:No Opinion
Price:87.50
De-listing on aim.
27 Dec '18
Just about says it all. Proposal to de-list announced on 19th December, and not a single posting here! What a pile of excrement this has turned out to be.
INFINITYT
Posts: 429
Opinion:No Opinion
Price:130.00
8 -1
19 Nov '18
For every 8 it is now just one so it is actually down. ( 16.25p @ 130 )
bbr391
Posts: 5,749
Opinion:No Opinion
Price:23.50
RE: Good news
8 Nov '18
The board of directors at Akers Biosciences Inc. said Wednesday the South Jersey medical-device company has "initiated a process to evaluate strategic alternatives to maximize shareholder value."

Based in Thorofare, Gloucester County, Akers develops and markets rapid screening and testing products for use in health care.

The board said the evaluations process will consider a range of potential strategic alternatives "including, but not limited to, business combinations." Akers said company representatives do not plan to disclose or comment on developments regarding the strategic review process until it is complete, or further disclosure is deemed appropriate.

“The board of directors and management of the company believes that now is the right time to review strategic alternatives to assess how best to maximize value for our shareholders," said Howard R. Yeaton, CEO of Akers. "During this process, the team will remain focused on advancing our current business operations and serving our customers.”

Yeaton was named CEO at Akers in October, the same month the company settled a lawsuit in part by agreeing to discontinue marketing efforts for its BreathScan OxiChek product or any product that detects oxidative stress in exhaled human breath.

The company said last month it will focus on its Particle Immuno-Filtration Assay (PIFA) technology platform that features a patented immunoassay method for rapidly and accurately detecting targeted antigens or antibodies. The technology platform is used in Akers PIFA Heparin/PF4 and PIFA Pluss/PF4 rapid assays that test for an allergic reaction to the blood-thinning medicine Heparin. These products, the company said, account for the “significant majority” of its revenues.

Akers also said Wednesday that the company to meet Nasdaq's minimum listing requirement of a minimum $1 per share stock price for companies listed on the exchange will implement a one-for-eight reverse stock split on Nov. 8.

TRENDING
BANKING & FINANCIAL SERVICES
Citizens Financial to acquire wealth management firm
As part of its continuing focus on expanding its fee product offerings, Citizens Financial Group has agreed to acquire a Westchester County, New York wealth management firm.
CAREER & WORKPLACE
Philadelphia Business Journal's Power 100, Part 5

COMING EVENT
Banking on Change: Greater Philadelphia’s Shifting Financial Landscape
Nov. 13

Its common stock will continue to trade on the Nasdaq Capital Market under the stock ticker "AKER."
bbr391
Posts: 5,749
Opinion:Strong Buy
Price:21.50
RE: Good news
16 Aug '18
Bounced up despite bad earnings .
Weird share Indeed .

Best of All
View more share chat for Akers Bio (AKR) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk











Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.